Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cannara BiotechLOVFF +2.03%88 3-Year EBITDA Growth Rate is 44.20% as of May. 2026, which is 15% below its 10-year median of 52.10. GuruFocus rates LOVFF with a GF Score™ of 88/100 and a GF Value™ of $1.22 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 809 Drug Manufacturers companies, Cannara Biotech ranks better than 87.14% on this metric.
During the past 12 months, Cannara Biotech's average EBITDA Per Share Growth Rate was -12.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 44.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cannara Biotech was 60.00% per year. The lowest was 44.20% per year. And the median was 52.10% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Cannara Biotech 3-Year EBITDA Growth Rate Related Terms
LOVFF vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannara Biotech 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Cannara Biotech's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 44.20% mean?
Cannara Biotech (LOVFF) has a 3-Year EBITDA Growth Rate of 44.20% as of May. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cannara Biotech and its competitors. This is 15% below median its historical median of 52.10. Over the past decade, Cannara Biotech's 3-Year EBITDA Growth Rate has ranged from 44.20 to 60.00. According to the industry distribution chart, Cannara Biotech ranks #104 out of 809 companies in the Drug Manufacturers industry, placing it in the top 12.9%.
Is Cannara Biotech's 3-Year EBITDA Growth Rate too high?
Cannara Biotech's current 3-Year EBITDA Growth Rate of 44.20% is 15% below median its 10-year median of 52.10. Over the past 10 years, this metric has ranged from a low of 44.20 to a high of 60.00. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Cannara Biotech's value of 44.20% is 396.6% above this industry median. Based on the distribution chart, Cannara Biotech ranks #104 out of 809 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cannara Biotech has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cannara Biotech ranks #104 out of 809 companies for 3-Year EBITDA Growth Rate. This places Cannara Biotech in the top 13% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Cannara Biotech's value of 44.20% is 396.6% above this benchmark. Historically, Cannara Biotech's own 3-Year EBITDA Growth Rate has ranged from 44.20 to 60.00 over the past decade. While the company's 10-year median is 52.10 vs. the industry median of 8.90, Cannara Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannara Biotech's current 3-Year EBITDA Growth Rate of 44.20% is 396.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cannara Biotech and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannara Biotech's current 3-Year EBITDA Growth Rate is 44.20%, which is 15% below median its own 10-year median of 52.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.22, compared to a current price of $1.46 — trading 19.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 44.20%, which is 15% below median its 10-year median of 52.10 and 396.6% above the Drug Manufacturers industry median of 8.90. Cannara Biotech's overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current 3-Year EBITDA Growth Rate is 44.20% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cannara Biotech (LOVFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cannara Biotech stock appears to be overvalued.
The current stock price of $1.46 is trading 19.7% above its estimated GF Value™ of $1.22.
GuruFocus considers Cannara Biotech to be Modestly Overvalued.
Key valuation signals for LOVFF:
3-Year EBITDA Growth Rate: 44.20% (15% below median its 10-year median of 52.10)
GF Value™: $1.22 vs. price of $1.46 (19.7% above fair value)
Industry Position: 396.6% above the Drug Manufacturers median (#104 of 809)
No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
88GF Score
Get the complete analysis for LOVFF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LOVFF has been successfully added to your 
